Kai Li ,Yongzhen Liu ,Changjun Liu ,Yanping Zhang ,Hongyu Cui , Xiaole Qi ,Jiayong Zhang ,Jia Xu ,Suyan Wang ,Yuntong Chen ,Yulu Duan ,Yulong Gao ,Xiaomei Wang

Vaccines (Basel).2024 Sep 13;12(9):1047.doi: 10.3390/vaccines12091047.

Abstract

The chicken infectious anemia virus (CIAV) has been reported in major poultry-producing countries and poses a significant threat to the poultry industry worldwide. In this study, two Marek's disease virus (MDV) recombinants, rMDV-CIAV-1 and rMDV-CIAV-2, were generated by inserting the CIAV VP1 and VP2 genes into the MDV vaccine strain 814 at the US2 site using the fosmid-based rescue system. For rMDV-CIAV-1, an internal ribosome entry site was inserted between VP1 and VP2, so that both proteins were produced from a single open reading frame. In rMDV-CIAV-2, VP1 and VP2 were cloned into different open reading frames and inserted into the MDV genome. The recombinant viruses simultaneously expressed VP1 and VP2 in infected chicken embryo fibroblasts and exhibited growth kinetics similar to those of the parent MDV. The two recombinant viruses induced antibodies against CIAV in chickens. A single dose of the recombinant viruses provided strong protection against CIAV-induced anemia in chickens. These recombinant VP1- and VP2-expressing MDVs are potential vaccines against CIAV in chickens.

Keywords: Marek’s disease virus; VP1; VP2; chicken infectious anemia virus; vaccine.